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Abstract
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are
common conditions with a rising burden. Yet there are significant management gaps
between clinical guidelines and practice in patients with NAFLD and NASH. Further,
there is no single global guiding strategy for the management of NAFLD and NASH.
The American Gastroenterological Association, in collaboration with 7 professional
associations, convened an international conference comprising 32 experts in gastroenterology, hepatology, endocrinology, and primary care providers from the United
States, Europe, Asia, and Australia. Conference content was informed by the results
of a national NASH Needs Assessment Survey. The participants reviewed and discussed published literature on global burden, screening, risk stratification, diagnosis,
and management of individuals with NAFLD, including those with NASH. Participants
identified promising approaches for clinical practice and prepared a comprehensive,
unified strategy for primary care providers and relevant specialists encompassing the
full spectrum of NAFLD/NASH care. They also identified specific high-yield targets
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for clinical research and called for a unified, international public health response to
NAFLD and NASH.

I NTRO D U C TI O N

the most recent practice guidance on NAFLD/NASH; and identify
the educational needs that could serve as targets to improve im-

Nonalcoholic fatty liver disease (NAFLD)—hepatic steatosis on imag-

plementation of guideline-b ased treatment of NAFLD and NASH.

ing or histology in the absence of known causes—is rapidly becom-

The survey included 24 questions regarding screening, diagnosing,

ing the most common cause of chronic liver disease worldwide (1).

and managing NASH (see online Supporting Information for the

Nonalcoholic fatty liver is histologically defined as the presence of

full survey). In total, 751 gastroenterologists, hepatologists, en-

≥5% hepatic steatosis without evidence of hepatocellular injury, and

docrinologists, and PCPs from 46 states across the United States

nonalcoholic steatohepatitis (NASH) is defined as the presence of ≥5%

completed the survey. More than 50% of survey participants were

hepatic steatosis and inflammation with hepatocyte injury (eg, bal-

PCPs. Respondents had spent an average of 19.5 years in practice

looning), with or without fibrosis (2). At least 20% to 30% of patients

(range, 2–35 years).

with NAFLD develop NASH, which can lead to cirrhosis and associ-

The survey revealed significant gaps in knowledge about who to

ated complications, including hepatocellular cancer (HCC) (2). NASH is

screen and how to diagnose and treat patients at high risk for NASH,

also associated with an increased risk of cardiovascular disease (3) and

including disparities between published practice guidance and clin-

increased cardiovascular and liver-related mortality (4–6).

ical practice (Table 1). Most respondents (67%) from all practice

Although most patients with NAFLD and NASH have tradition-

types were aware that up to one-quarter of the general population

ally been diagnosed and managed by hepatologists, the recent avail-

may have NAFLD. However, there were shortfalls in the knowledge

ability of noninvasive diagnostic procedures is expanding the role of

about prevalence in several high-risk groups. For example, only 35%

other health care professionals likely to see patients with these con-

of all respondents—including 28% of endocrinologists, 32% of PCPS,

ditions, particularly gastroenterologists, endocrinologists, obesity

and 46% of gastroenterologists/hepatologists—recognized that al-

medicine specialists, and primary care providers (PCPs). Previous

most all patients with severe obesity are likely to have NAFLD. Only

research has suggested that effectively treating NASH will require

49% of endocrinologists and 45% of PCPs recognized that NAFLD is

more education about both NAFLD and NASH among specialists and

very common in patients with type 2 diabetes (T2D) (Table 1).

PCPs (7). Some published data also showed significant management

Most participants reported that they screen patients with ab-

gaps between published guidance and clinical practice in patients

normal liver chemistries (96%), those with T2D (87%), and those

with NAFLD and NASH (8,9). Much of this disparity could come from

who are older than 50 years with hypertension and hyperlipidemia

a lack of recognition of the importance of NAFLD/NASH and an ab-

(70%) for the presence of NAFLD. Most were also aware of the best

sence of a unified strategy that encompasses all disciplines involved

practices in the initial evaluation of patients with suspected NAFLD,

in managing these patients across the full disease spectrum.

including the need to exclude competing etiologies (96%) and evalu-

To address this need, the American Gastroenterological Association

ation for commonly associated comorbidities, such as T2D, obesity,

(AGA) conducted a needs assessment survey of health professionals

and dyslipidemia (96%). However, only 41% recognized that initial

likely to be engaged in managing adult patients with NAFLD/NASH,

evaluation of patients with suspected NAFLD should not include

followed by a virtual conference of international experts representing

cross-sectional abdominal imaging (eg, contrast-enhanced com-

7 professional societies to review the current research and outline the

puted tomography) to screen for HCC. There were no significant dif-

future agenda for clinical practice, research, and policy. The overarch-

ferences in the responses among gastroenterologists/hepatologists,

ing goal was to call for a unified, international public health response to

endocrinologists, and PCPs.

NAFLD and NASH. This report summarizes the results from the survey

More than 80% of participants were aware that noninvasive

and the virtual conference, “Preparing for a NASH Epidemic: A Call for

tests, including the NAFLD fibrosis score, Fibrosis-4 Index, and

Action.” Although NAFLD is an important and growing problem in chil-

imaging-based tests, such as vibration-controlled transient elas-

dren, the current effort was limited to adults with NAFLD and NASH.

tography or magnetic resonance elastography, are clinically useful

Therefore, we do not cover pediatric NAFLD in this report.

tools for identifying NAFLD/NASH patients with a high likelihood of
advanced liver fibrosis. However, 78% also thought that abdominal

N A S H N E E DS A S S E S S M E NT S U RV E Y

ultrasound can identify NAFLD patients with NASH.
Most participants were aware that 7% to 10% weight loss is
recommended for patients with NAFLD, but fewer than half of the

The NASH Needs Assessment Survey was conducted in May

participants were aware that pioglitazone or vitamin E can be rec-

2020. The survey sought to assess participants’ knowledge re-

ommended as treatment in select patients with NASH. Most respon-

lated to screening, diagnosis, and management of NAFLD and

dents (>80%) wanted more education about screening, diagnosis,

NASH; compare current diagnostic and treatment patterns with

and treatment of NAFLD/NASH.

|
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TA B L E 1 Key results from the nonalcoholic steatohepatitis (NASH) needs assessment survey
All participants
(n = 751)

Gastroenterologists/
hepatologists (n = 175)

Endocrinologists
(n = 175)

Primary care
(n = 401)

Patients with severe obesity

35

46

28

32

Patients with T2D

50

62

49

45

Patients with dyslipidemia

40

47

41

36

General population

67

79

65

62

Patients with abnormal liver chemistry

96

97

97

85

Patients with T2D

87

88

94

83

Patients older than 50 years who have hypertension and
hyperlipidemia

70

81

73

67

Exclude competing etiologies for steatosis and coexisting
common chronic liver disease

96

95

95

97

Consider the presence of commonly associated
comorbidities, such as obesity, dyslipidemia, insulin
resistance, or diabetes

95

97

93

95

Cross-sectional abdominal imaging (such as contrast-
enhanced CT scan) to screen for HCC

41

50

39

38

NAFLD fibrosis score or Fibrosis-4 Index are useful tools
for identifying NAFLD patients with high likelihood of
advanced fibrosis

82

94

86

75

VCTE (FibroScan) or MRE (imaging) are useful tools for
identifying advanced fibrosis in patients with NAFLD

81

93

85

74

Abdominal ultrasound is a useful tool for identifying
NAFLD patients with steatohepatitis

16

29

18

9

GLP-1 agonists

16

21

15

15

Metformin

17

33

17

11

Obeticholic acid

15

33

13

9

Omega-3 fatty acids

23

37

23

16

Variable
Proportions of the key patient groups likely to have NAFLD

Patient groups that should be screened for NAFLD

Approaches to the initial evaluation of the patient with
suspected NAFLD

Knowledge about strategies for noninvasive diagnosis of
steatohepatitis and advanced fibrosis in NAFLD

Appropriateness of treatments for NASH

a

53

53

77

42

Ursodeoxycholic acid

22

49

17

12

Vitamin E for nondiabetic adultsa

40

71

51

38

Pioglitazone

Data represent percentages of participants who answered the item correctly.
Abbreviations: CT, computed tomography; GLP-1, glucagon-like peptide 1; HCC, hepatocellular cancer; MRE, magnetic resonance elastography; T2D,
type 2 diabetes; VCTE, vibration-controlled transient elastography.
a

The estimates for pioglitazone and vitamin E indicate percentages of participants who would consider treatment overall (with or without liver
biopsy).

A C A LL-TO -AC TI O N CO N FE R E N C E

In a series of preconference meetings conducted over 2 months
(May and June 2020), these key opinion leaders met and discussed
the most important and potentially controversial aspects of the cur-

To address these knowledge gaps, the AGA convened a virtual con-

rent NAFLD/NASH landscape, including epidemiology, risk factors,

ference of international experts in gastroenterology, hepatology,

screening, diagnosis, and management issues. Formal presentations

endocrinology, obesity management, and primary care on July 10,

by each participant followed during the 1-day conference, which

2020. Participants represented key opinion leaders from 8 profes-

included the best-available evidence about their topic. Subsequent

sional societies, and practiced in the United States, Europe, Australia,

to the meeting, workgroups (predefined by subject) reviewed, dis-

and Asia. See the online Supporting Information for the names and

cussed, and collated a summary from all presentations in their re-

affiliations of all participants.

spective sections, followed by an internal review of the summary

1404
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from all workgroup members. The final manuscript (including sum-

found that, compared to NAFLD patients with no fibrosis (stage 0),

maries from each workgroup) was then submitted to the full group

patients with fibrosis were at an increased risk for all-cause mor-

for a second round of input and approval. The sections here detail

tality, and this risk increased with the stage of fibrosis: stage 1: risk

the discussion, conclusions, and recommendations for clinical prac-

ratio (RR) vs stage 0, 1.58 (95% confidence interval [CI], 1.19–2.11);

tice and future research that emerged from this process.

stage 2: RR, 2.52 (95% CI, 1.85–3.42); stage 3: RR, 3.48 (95% CI,
2.51–4.83); and stage 4: RR, 6.40 (95% CI, 4.11–9.95). The results

B U R D E N O F N A FLD a n d N A S H

were more pronounced for risk of liver-related mortality, which increased exponentially with each increase in fibrosis stage, from an
RR of 1.41 (95% CI, 0.17–11.95) for stage 1 to an RR of 9.57 (95% CI,

The clinical burden of both NAFLD overall and NASH specifically

1.67–54.93) for stage 2, and an RR of 42.30 (95% CI, 3.51–510.34)

has increased steadily since the 1980s. NAFLD currently affects

for stage 4 fibrosis (5).

25% of the global population and >60% of patients with T2D(10).

Notably, fibrogenesis does not proceed linearly from simple fatty

Studies evaluating the prevalence of NASH suggest that it may in-

liver to NASH to cirrhosis, but progresses and regresses in up to 30%

volve an estimated 1.5% to 6 .5% of the general population and as

of patients during a mean period of 5 years (20). Furthermore, many

many as 37% of people with T2D (10). Prevalence of NASH is ex-

patients with isolated hepatic steatosis, previously thought to be be-

pected to increase by 63% between 2015 and 2030 (11). Although

nign, are likely to progress to NASH (20). On average, patients with

these numbers seem substantially lower than those for NAFLD

NASH and NAFLD progress 1 stage of fibrosis every 7 and 14 years,

overall, they still translate to 4.9 million to 21 million Americans

respectively (21). Older age, visceral obesity, T2D, and hypertension

and more than 100 million individuals worldwide. Modeling data

are associated with fibrosis progression (21,22). T2D and number of

estimate that the number of patients with NASH-related advanced

metabolic comorbidities are also associated with an increased risk

fibrosis will likely double by 2030, resulting in 800,000 liver-

of liver-related mortality and HCC (23,24). The severity of steatosis,

related deaths (11).

however, has a modest (if any) correlation with the severity of liver

NASH is already the number 1 indication for liver transplantation in women, patients older than 54 years, and Medicare recipients

histology (25), and the relationship between severity of steatosis
and cardiovascular disease remains unclear.

(12). Beyond the significant impairment of quality of life experienced
by individuals with NASH and advanced fibrosis (10,13), Younossi
et al (14) estimated in 2017 that the overall lifetime direct costs of

Screening and diagnosis

NASH in the United States would be $222.6 billion, and approximately $95.4 billion over the next 2 decades, suggesting a substan-

Effectively screening for and timely diagnosis of NAFLD may pre-

tial economic burden.

vent progression to NASH and associated complications. Because
PCPs are on the front lines of managing individuals with NAFLD,

R I S K FAC TO R S FO R N A FLD, N A S H , A N D
R E L ATE D CO M PLI C ATI O N S

screening patients at risk, stratifying patients based on their risk for
advanced fibrosis, and positioning themselves to provide effective
management and referrals are important. A recent study showed
that screening for NAFLD followed by intensive lifestyle interven-

Patients with obesity or T2D are at a higher risk of developing

tions or pioglitazone was cost-effective in patients with T2D diag-

NAFLD/NASH (15,16). Conversely, patients with NAFLD are at an

nosed with clinically significant fibrosis, providing support for these

increased risk of T2D (17). NAFLD and especially NASH are indepen-

recommendations (26).

dently associated with several liver-related complications, including
cirrhosis, HCC, and liver-related mortality. Patients with NAFLD

To recognize NAFLD, the PCP must be aware of the following
facts:

also have a 2-fold increase in risk of cardiovascular disease (18,19).
Indeed, individuals with NAFLD/NASH are twice as likely to die of

1. NAFLD is the one of the most common causes of abnormal

cardiovascular disease as liver disease (17). The risk of cardiovas-

liver enzymes, but serum alanine aminotransferase (ALT) and

cular disease in NAFLD is not completely explained by the shared

aspartate aminotransferase (AST) can be normal in many cases

risk factors, and might be related in part to abnormalities of cardiac

of NAFLD/NASH at all stages, including in patients with ad-

structure and function (17).
In patients with NAFLD, the strongest histologic determinant of
hepatic and overall outcomes is the presence and stage of fibrosis,

vanced fibrosis (27).
2. Liver fibrosis has been linked to morbidity and reduced overall
patient survival (28).

although the presence of NASH is the driving force for fibrosis de-

3. NAFLD and fibrosis are reversible with weight loss (29).

velopment. Patients with histologic evidence of fibrosis higher than

4. Alcohol causes fatty liver disease with many histologic features

stage 2 are at higher risk for adverse outcomes (hepatic decompen-

of NAFLD. Although good clinical history is extremely important,

sation, HCC, and liver-related mortality), and this risk increases as

one way to differentiate alcoholic from nonalcoholic fatty liver is

fibrosis advances to cirrhosis (5). Specifically, a recent meta-analysis

the AST/ALT ratio, which is generally ≥2 in patients with alcohol
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as the underlying cause. In certain patients, selective testing for

tests are not approved in the United States, limiting their use in clin-

alcohol metabolites may also be appropriate.

ical practice. In contrast, elastography-based tests are available and
can be used for risk stratification. Several recent studies show that

Clinical practice guidelines do not recommend screening for

this sequential use of noninvasive tests reduces unnecessary refer-

NAFLD in the general population, but case finding for NASH and

rals to specialists, increases the detection of advanced fibrosis and

significant fibrosis is advised for key high-risk groups, such as those

cirrhosis, and hence may be cost-effective (36,37).

with moderate to severe obesity (BMI >35 kg/m2), T2D of more than

Once diagnosis and initial risk stratification have been com-

10 years’ duration or in people older than 50 years, or metabolic syn-

pleted, a more detailed assessment of liver fibrosis is essential.

drome (30). The American Diabetes Association’s 2020 Standards of

Accurate fibrosis staging provides information regarding prognosis,

Medical Care in Diabetes also recommend evaluating patients with

need for pharmacotherapy, intensive lifestyle modification and/or

prediabetes or T2D with steatosis or elevated ALT for NASH and

bariatric surgery, and screening/surveillance for varices and HCC.

fibrosis (31).

The most commonly used imaging techniques to evaluate fibrosis

Diagnosing NAFLD/NASH begins with evaluating patients for al-

are vibration-controlled transient elastography and magnetic res-

ternative or coexisting causes of liver disease, such as viral hepatitis

onance elastography. Vibration-controlled transient elastography

or significant alcohol intake, through history and laboratory testing

uses ultrasound waves to investigate the presence or absence of

(Table 2). The accuracy of ultrasound for the detection of moderate

advanced fibrosis with a specificity of 92% (38). Magnetic resonance

and severe steatosis is quite high, >80% in a meta-analysis compared

elastography can identify the intermediate stages of fibrosis more

to that of liver biopsy. However, ultrasound has suboptimal sensi-

readily, but is not as widely available and is much more costly (30).

tivity for mild steatosis (32,33). Among patients with a high pretest

Liver biopsy, historically required to diagnosis liver fibrosis and

probability of NAFLD, moving directly to risk stratification without

NASH, provides helpful information and should be considered for

an ultrasound to confirm steatosis may be appropriate.

cases in which there is a diagnostic doubt, such as patients with in-

Although an optimal strategy for risk stratification of individu-

determinate, unreliable, or conflicting noninvasive assessments, or

als with NAFLD/NASH in primary care and specialist clinics remains

as part of phase 2 or 3 clinical trials. In addition to excluding co-

undefined, the guiding principle is to rule out advanced fibrosis by

existent liver diseases, liver biopsy allows for assessment of disease

simple, noninvasive fibrosis scores (such as NAFLD fibrosis score or

activity in the form of lobular and portal inflammation and balloon-

Fibrosis-4 Index). Patients at intermediate or high risk may require

ing degeneration (a marker of liver-cell injury). These 2 processes

further assessment with a second-line test—elastography, or a serum

are thought to be responsible for triggering the development of liver

marker test with direct measures of fibrogenesis (such as enhanced

fibrosis.

liver fibrosis (34) or fragments of propeptide of type III procollagen

Assessment of cardiometabolic risk in NAFLD/NASH is also im-

(35), and may require referral to a hepatology clinic (Figure 1). Of note,

portant, especially in patients who are at intermediate to high risk of

the enhanced liver fibrosis and propeptide of type III procollagen

advanced fibrosis (39). The Atherosclerotic Cardiovascular Disease

TA B L E 2 Initial evaluation in patients with suspected
nonalcoholic fatty liver disease (NAFLD)

guidance for statin use (40).

History and medical
review

Investigations

Obesity

Liver biochemistries (ALT, AST)

T2D

Exclude/identify other liver diseasesa

Most patients with NAFLD and many with NASH have a low risk of

Metabolic syndrome

HBV and HCV serology (and viral load)

clinically significant fibrosis and can be managed by PCPs. Because

Alcohol intake

Auto antibodies (ANA, AMA, ASMA)

NAFLD is not an isolated disease but a component of cardiometa-

<14 drinks/wk for
women

Serum ferritin, A1AT

<21 drinks/wk for men

Liver ultrasound: increased echogenicity

No known pre-existing
liver disease

—

Abbreviations: A1AT, α1 antitrypsin; ALT, alanine aminotransferase;
AST, aspartate aminotransferase; AMA, antimitochondrial antibody;
ANA, antinuclear antibody; ASMA, anti–smooth muscle antibody; HBV,
hepatitis B virus; HCV, hepatitis C virus; T2D, type 2 diabetes.
a

risk calculator has been validated in NAFLD patients and provides

NAFLD can coexist with other chronic liver diseases. Of note, 21% of
patients with NAFLD may have elevations in autoantibodies in the absence
of autoimmune hepatitis (85), and 20% may have high serum ferritin (>300
ng/mL in women and >450 ng/mL in men). Elevated serum ferritin is
associated with advanced hepatic fibrosis (86) in patients with NAFLD.

Management

bolic abnormalities typically associated with obesity, the cornerstone of therapy is the same as that for people with obesity and
cardiometabolic complications, namely lifestyle-based therapies
(altered diet, such as reduced-calorie or Mediterranean diet and regular, moderate physical activity), and replacing obesogenic medications to decrease body weight and improve cardiometabolic health.
The magnitude of weight loss correlates with decreases in intrahepatic triglyceride (IHTG) content, hepatocyte ballooning, and hepatic
inflammation (29).
IHTG is extraordinarily sensitive to changes in energy balance;
even 48 hours of a low-calorie diet can decrease IHTG by about
20%, and 7% weight reduction decreases IHTG by approximately
40% (41). The durability of these acute weight-loss–related changes

1406
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F I G U R E 1 Algorithm for risk stratification in patients with NAFLD/NASH. FIB-4, Fibrosis-4 Index; NFS, NAFLD fibrosis score [Color
figure can be viewed at wileyonlinelibrary.com]
remains to be determined. Furthermore, hepatic fibrosis is more re-

first-line therapy for the pharmacologic management of T2D, it is

sistant to weight loss and requires larger amounts (≥10%) and pos-

not effective in treating NASH (2,25). Guidelines suggest that clini-

sibly longer duration of weight loss to achieve clinically meaningful

cians should instead consider using pioglitazone (a thiazolidinedione

outcomes. Regular endurance (42,43) or resistance exercise (44) in

acting through activation of proliferator-activated receptor–γ and

the absence of weight loss decreases IHTG content only slightly

–α agonism), based on evidence from 5 randomized controlled trials

but improves metabolic health. US Food and Drug Administration–

showing that it reverses steatohepatitis in patients with (48–50) and

approved weight-loss medications can enhance weight loss induced

without (45,49) diabetes. In the phase 3 Pioglitazone vs Vitamin E vs

by lifestyle therapy and may contribute to the successful manage-

Placebo for Treatment of Non-Diabetic Patients with Nonalcoholic

ment of patients with NAFLD. Patients at risk of significant fibrosis

Steatohepatitis (PIVENS) trial, pioglitazone led to resolution of ste-

(based on their clinical profile, blood test panels, and/or imaging)

atohepatitis in 47% of patients compared with 21% of patients in

should be referred to a hepatologist to discuss the need for further

the placebo group (p = 0.001; vitamin E in 36%; p = 0.05), although

testing, including biopsy, appropriate follow-up (particularly for

pioglitazone did not meet the prespecified primary end point (45).

those patients with advanced fibrosis/cirrhosis), and possible inclu-

Studies of patients with prediabetes or T2D with follow-up for up

sion in NASH clinical trials (Figure 1).

to 3 years have also consistently reported benefit with pioglitazone

Patients with NASH and fibrosis stage 2 or higher are candi-

treatment (48–50).

dates for liver-directed pharmacotherapy (Table 3). Although there

Based on these data, the American Association for the Study of

are currently no US Food and Drug Administration–approved drugs

Liver Diseases, the European Association for the Study of the Liver,

for treating NASH, vitamin E (800 IU/d) improves steatosis in NASH

European Association for the Study of Diabetes, and European

patients without T2D (45). Although randomized controlled trials

Association for the Study of Obesity guidelines suggest that piogl-

have not shown similar efficacy in patients with T2D (46), one ret-

itazone can be used for NASH patients with diabetes. The guide-

rospective study of patients with NASH and either bridging fibrosis

lines also state that vitamin E (administered at a daily dose of 800

or cirrhosis, with or without T2D, associated vitamin E with greater

IU) may be considered in nondiabetic adults with biopsy-proven

transplant-free survival and lower rates of hepatic decompensation

NASH (2,30). Pioglitazone can also reduce cardiovascular disease

(47).

in patients with or without T2D, as reviewed elsewhere, although

If diabetes is present, the PCP may opt to prescribe a medication for diabetes that can also treat NASH. Although metformin is

the US Food and Drug Administration has not approved it for this
indication (51,52).
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TA B L E 3 Management of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH)
Variable

a

Liver-directed
pharmacotherapy

Diabetes care (in individuals
with diabetes)

Cardiovascular
risk reduction

Nonalcoholic fatty liver

Yes

No

Standard of care

Yes

NASH with fibrosis stage 0 or 1 (F0, F1)

Yes

No

Standard of care

Yes

NASH with fibrosis stage 2 or 3 (F2, F3)

Yes

Yes

Pioglitazone, GLP-1 receptor
agonistsb

Yes

NASH cirrhosis (F4)

Yes

Yes

Individualizec

Yes

All patients require regular physical activity and healthy diet and to avoid excess alcohol intake; weight loss recommended.

b
c

Lifestyle
interventiona

Among glucagon-like peptide 1 (GLP-1) receptor agonists, semaglutide has the best evidence of benefit in patients with NASH and fibrosis.

Evidence for efficacy of pharmacotherapy in patients with NASH cirrhosis is very limited and should be individualized and used with caution.

Several glucagon-like peptide 1 (GLP-1) receptor agonists and

Despite the promise of antidiabetes medications, the role of im-

SGLT2 inhibitors, which are increasingly used in T2D, as they re-

proving glycemic control on the natural history of NASH and de-

duce cardiovascular risk and promote weight loss, also potentially

velopment of cirrhosis remains poorly understood, and the role of

decrease hepatic steatosis in patients with NAFLD. GLP-1 receptor

glycemic control of disease progression in NASH remains to be es-

agonists (dulaglutide, exenatide, liraglutide, and semaglutide) have

tablished. Improving glycemic control with insulin therapy reduces

been tested in patients with T2D and NAFLD, with the most robust

liver steatosis (48), but its impact on liver histology (both NASH or

evidence to date involving semaglutide (53–57). A small phase 2 trial

fibrosis) and the natural history of the disease remain unknown.

(involving 52 patients) that evaluated liraglutide, a synthetic long-

Cross-sectional (59) and longitudinal observational studies (60) do

acting GLP-1 receptor agonist available for treating T2D and obesity,

not show a clear correlation between hemoglobin A1c levels over

resulted in weight loss, resolution of steatohepatitis, and slower pro-

time and liver histology or other clinical outcomes. Lowering he-

gression of fibrosis than placebo, although gastrointestinal adverse

moglobin A1c levels with pioglitazone treatment for 18 months has

effects were common (56). More recently, a report in 320 patients

been associated with improvement in NASH and slower progression

with biopsy-proven NASH offers the strongest evidence for the use

of fibrosis compared to patients with diabetes on placebo but, over-

of GLP-1 receptor agonists in patients with NASH using subcutane-

all, the histologic response to pioglitazone does not appear to be

ously administered semaglutide at doses of 0.1, 0.2, or 0.4 mg/d (54).

linked to improved glycemic control, as it is similar in patients with vs

This 72-week study included a population in which 62% of patients

those without diabetes (49).

had T2D and >70% had moderate to advanced stage F2–3 liver fi-

Bariatric surgery is currently the most effective therapy avail-

brosis. The primary outcome, NASH resolution without worsening

able for obesity. The 2 most common procedures are sleeve

of fibrosis, was achieved in 40%, 36%, and 59% of patients treated

gastrectomy and Roux-en-Y gastric bypass. Marked weight loss (ap-

with semaglutide at doses of 0.1, 0.2, and 0.4 mg/d, respectively,

proximately 25%–35%) induced by bariatric surgery has profound

vs 17% on placebo. Of note, the proportion of patients with liver

effects on steatosis, NAFLD activity score, hepatocyte ballooning,

fibrosis improvement (approximately 30%–4 4%) did not reach sta-

and lobular inflammation, and results in NASH resolution in most

tistical significance in any arm. The reasons remain unclear, although

patients (61,62). Surgery-induced weight loss also has a consider-

worsening of fibrosis occurred in 10%, 8%, and 5% of the patients in

able therapeutic effect in reducing stages 1 and 2 fibrosis, but is

the semaglutide 0.1, 0.2, and 0.4 mg groups, respectively, and in 19%

less effective in improving stages 3 and 4. Bariatric endoscopy is

of the patients in the placebo group (54). Of note, the dose used in

emerging as a new treatment for obesity, but the long-term durabil-

the study is not currently available for prescription in patients with

ity of its effects remains to be determined. About 15% weight loss

diabetes, but the weight loss and metabolic effects achieved were

has been reported after therapy with a postprandial gastric aspira-

similar overall to the effects seen with currently available dose for

tion device, which is associated with reduced plasma AST and ALT

management of diabetes. Physicians unfamiliar with or unable to

(63), whereas duodenal mucosal resurfacing has reduced Fibrosis-4

prescribe these medications should consider referring patients to

Index scores by mechanisms possibly unrelated to weight reduction

an endocrinologist, diabetologist, or obesity medicine specialist (53).

(64). Intragastric balloon placement has also been associated with

Another small recent study found that dulaglutide also reduced

histologic improvement in individuals with NASH (65), although

liver fat content and transaminases in people with T2D and NAFLD

findings remain preliminary. Patients with advanced liver disease,

(55). These findings allow the possibility of treating diabetes, car-

especially with hepatic decompensation, have higher mortality after

diovascular disease, and NASH simultaneously with diabetes med-

bariatric surgery. Overall, more efficacy and safety data are needed

ications, such as pioglitazone or a GLP-1 receptor agonist. SGLT-2

before these approaches can be recommended as treatment op-

inhibitors (canagliflozin, dapagliflozin, empagliflozin, and ertugli-

tions for patients with NAFLD and NASH.

flozin) have also been tested in NAFLD, but these studies have been

Special attention to the management of sedentary behavior, as

small and do not examine the effect of these agents on liver histol-

well as to dyslipidemia, diabetes, and hypertension, is recommended

ogy (58).

for all individuals with NAFLD (66). Alcohol consumption should be
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limited to 2 to 3 drinks per week in women and 4 to 5 drinks per

regimens may ultimately be needed to treat NASH most effectively

week in men and avoided in patients with advanced fibrosis (67,68),

(80,81).

although high-quality data on the exact risk of progressive liver disease in patients with advanced fibrosis are still needed. Many PCPs
and nonhepatologists discontinue statins when liver enzymes are
elevated (9,69,70). However, numerous studies have also demonstrated that statins are safe and efficacious in patients with NAFLD
and NASH, and they can be used to treat dyslipidemia in these pa-

R ECO M M E N DATI O N S
Develop more sensitive and specific diagnostic
methods

tients, including those with compensated cirrhosis. Statins have
pleiotropic properties that may be directly beneficial in liver disease.

The invasive nature and relatively high expense of liver biopsy limit

In a meta-analysis of 13 studies, including 3 randomized controlled

its use and call for more sensitive and specific noninvasive diagnos-

trials, statin use in cirrhosis was associated with a reduction in he-

tic methods for NASH. Several novel noninvasive tools with the po-

patic decompensation (hazard ratio, RR, 0.54; 95% CI, 0.46–0.62)

tential to provide more sensitive and specific diagnosis are currently

and lower mortality (hazard ratio, 0.54; 95% CI. 0.47–0.61) (71).

under development. These include top–down approaches, such as

However, because data remain limited regarding safety and risks

multiomics and narrowing down to the minimum number of mole-

of statins in patients with decompensated cirrhosis (72,73), statins

cules that could provide the maximum positive and negative predic-

should be avoided until we have stronger evidence to support their

tive value (82,83).

safety in these patients. The AGA clinical practice update provides
some guidance and advises against statin use among patients with
Child-Pugh class B or C cirrhosis (74). The underlying rationale is that

Adopt a multidisciplinary approach to NASH

the generally grave liver-related prognosis of patients with Child-
Pugh class B or C cirrhosis makes it unlikely that they will benefit

Optimal care of patients with NASH may require clinicians from a

from the cardiovascular benefits associated with lipid-lowering ther-

variety of specialties, including primary care, hepatology, obesity

apy. In a large retrospective cohort study of statins in patients with

management, and endocrinology, to tackle both the hepatic mani-

cirrhosis, the survival benefit did not extend to patients with Child

festations of the disease and the comorbid metabolic syndrome and

class C cirrhosis (75).

cardiovascular risk, as well as screening and treating other comorbid
conditions (eg, obstructive sleep apnea). When NAFLD progresses

Emerging tools

to NASH, multidisciplinary, team-based care involving these specialties is crucial. Improving the traditional model of primary, secondary, and tertiary care will require not only developing and validating

Given the high prevalence of NAFLD and the limited patient aware-

algorithmic approaches (eg, who can be managed where and how),

ness about this disease, applying artificial intelligence/machine learn-

but also connectivity and multidirectional referrals among these

ing tools to the big data repositories of electronic health records holds

practice settings. Examining other models of care, such as medi-

considerable potential for efficient disease identification and risk

cal homes either dedicated to NAFLD/NASH or incorporated within

stratification (76). “Machine learning” is a subset of artificial intelli-

similar homes that manage metabolic disease more broadly, could

gence in which computer algorithms are improved through experience

also be valuable in developing care models. These integrated mod-

(77). These tools can produce noninvasive calculated scores by using

els can create and align expertise and incentives among different

information about patient demographic and clinical characteristics

specialties.

from both narrative (ie, free text) and codified (eg, administrative disease codes and laboratory tests) sources. Artificial intelligence is also
being tested to improve the accuracy and reliability of liver histologic

Develop clinical care pathways

interpretation using quantitative scoring systems for NAFLD/NASH
radiologic and histopathologic features (78,79). However, although the

Developing clinical care pathways that use validated and efficient

availability of noninvasive tests to accurately assess response to treat-

noninvasive tests and calculators is crucial to a multidisciplinary

ment beyond histopathology would greatly facilitate the efficient en-

approach to managing NAFLD/NASH. Clinical care pathways,

rollment in NASH treatment clinical trials, existing options still require

with careful explication of each step-in screening, diagnosis, and

further validation and eventual acceptance by regulatory agencies.

treatment, have been shown to improve the quality of health care

Several liver-t argeted and other potential therapies are also

delivery in other areas of medicine. Members of the NASH: A Call-

currently under investigation, targeting a broad range of patho-

to-Action Steering Committee and several other conference partici-

logic changes associated with NASH, including insulin resistance,

pants are currently developing such a pathway for NAFLD/NASH.

alterations in the microbiome and gut permeability, oxidative stress,

Rapid and timely dissemination of these pathways to all stakehold-

apoptosis, lipotoxicity, inflammation, and bile acid metabolism. Given

ers, especially the frontline PCPs, will be important in developing a

the multiple pathways involved in NASH pathogenesis, combination

systematic approach to managing NAFLD/NASH.

|

There is also a large unmet need for programs that can increase
disease awareness in the medical community and the general population. Finally, the closely interlinked nature with related metabolic
diseases suggests that reducing the clinical and economic burden of
NASH and NAFLD will require fundamental societal changes driven
by policies to address failing public health systems and the social

changes and innovations in technology, health care delivery, and policy. In addition, optimal care of patients with NAFLD/NASH will require a multidisciplinary team integrating primary care, hepatology,
obesity medicine, and endocrinology/diabetology via well-defined
care pathways, along with exploration of the high-yield targets for
clinical research and practice identified by conference participants.
These efforts should help the field move toward a collective strategy with shared goals and objectives that will improve care for the
growing population of patients with NAFLD/NASH.O

2016

disease severity stratification, and treatment will require significant

National Institute for Health Care and
Excellence (NICE)

spectrum of care for patients with NAFLD from screening, diagnosis,

2012

gists, and hepatologists, on a collective action plan. Improving the

World Gastroenterology Organization (WGO)

ogists, diabetologists, obesity medicine specialists, gastroenterolo-

2016

steps needed to align key stakeholders, including PCPs, endocrinol-

European Association for the Study of the Liver
(EASL)

Action Meeting described in this report represents one of the first

2012

geoning population continue to work in separate silos. The Call-to-

American Gastroenterological Association (AGA)

be achieved if the different specialties engaged in managing this bur-

Not clear in the guideline

cohorts, such as patients with diabetes and obesity. This goal cannot

2018

the United States and globally, particularly among emerging at-risk

American Association for the Study of Liver
Diseases (AASLD)

menting effective screening, diagnosis, and treatment strategies in

First-line diagnosis test

derscores the importance and urgency of developing and imple-

Year

The upward trend in NAFLD/NASH incidence and prevalence un-

Organization

S U M M A RY A N D CO N C LU S I O N S

TA B L E 4 Summary of published nonalcoholic fatty liver disease (NAFLD) guidelines

determinants of health.

Not clear in the guideline

ence and clinical practice of managing NAFLD/NASH.

Ultrasound + liver enzymes for patients with risk
factors

cence to adulthood to be evaluated, are needed to inform the sci-

Ultrasound + liver enzymes for patients with risk
factors

cohorts that allow the transition from childhood through adoles-

Routine screening for NAFLD is not
recommended

with longitudinal data on clinical course and outcomes, particularly

Routine screening for NAFLD in high-risk groups
is not recommended

specific to NAFLD/NASH-related cirrhosis. In addition, large cohorts

Not clear in the guideline

When to refer to hepatologist

sis literature, new data and updated guidelines are needed that are

Not clear in the guideline

in NAFLD is derived from the viral hepatitis and alcoholic cirrho-

Refer patients with abnormal liver
enzymes or medium-/high-risk
fibrosis markers to specialist

because virtually all current guidance regarding HCC surveillance

Abbreviations: FIB-4, Fibrosis-4 Index; NFS, NAFLD fibrosis score.

screening, diagnosis, and therapy is urgently required. Furthermore,

Refer children with suspected NAFLD to
a pediatric specialist in hepatology

Intersociety collaboration for harmonizing guidelines to optimize

But routine liver function blood tests are not
sensitive, and ultrasound is not cost-effective

and existing guidelines often conflict with one another (Table 4).

1409

Assessment for advanced fibrosis:
enhanced liver fibrosis (every 2–3 years)

clear screening, testing, or referral guidelines for NAFLD/NASH,

Refer adults with advanced liver fibrosis
to a hepatologist

For example, not all hepatology/gastroenterology societies have

Ultrasound + liver enzymes for patients with risk
factors

Noninvasive tests

of these countries (84). This deficit has even more proximal roots.

Diagnosis for NASH: liver biopsy

NAFLD/NASH management strategy or action plans in every one

Assessment for fibrosis: NFS or FIB-4

vey of 29 European countries highlighted the absence of a concrete

Diagnosis for NASH: liver biopsy

is no single guiding strategy in the United States or Europe. A sur-

Assessment for fibrosis: NFS or FIB-4

The public health response to NAFLD remains rudimentary. There

Diagnosis for NASH: liver biopsy

Pursue a unified, international public health response

Metabolic syndrome can be used to target
patients for liver biopsy

PREPARING FOR THE NASH EPIDEMIC: A CALL TO ACTION
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